February 20, 2025, Harbour BioMed (HKEX: 02142, the "Company"), a global biopharmaceutical company committed to the discovery ...

ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) ("IPA" or the "Company"), a global leader in AI-powered antibody discovery and ...

Anti-CD20 mAbs were originally created to treat B cell proliferative diseases such as non-Hodgkin's lymphoma and chronic ...

Harbour BioMed (HKEX: 02142, the "Company"), a global biopharmaceutical company committed to the discovery, development and commercialization of novel antibody therapeutics focusing on immunology and ...

Harbour BioMed (HKEX: 02142, the "Company"), a global biopharmaceutical company committed to the discovery, development and ...

Harbour BioMed, a global biopharmaceutical company committed to the discovery, development and commercialization of novel ...

Japanese drugmaker Chugai Pharmaceutical today announced gaining regulatory approval from the Ministry of Health, Labor and ...

Researchers’ understanding of the pathogenesis of rheumatoid arthritis has grown considerably in recent years, laying the ...